The article reports the FDA’s decision on ivonescimab plus chemotherapy for previously treated EGFR-mutated NSCLC, the agency’s rationale, and the HARMONi trial results supporting the application.
Approach:
Regulatory decision: The FDA issued a Complete Response Letter, saying the application could not be approved in its present form because substantial evidence of effectiveness had not been established without a statistically significant overall-survival improvement.
Evidence reviewed: The application was supported by HARMONi, a global, randomized, double-blind phase 3 trial in patients with EGFR-mutated, locally advanced or metastatic nonsquamous NSCLC previously treated with a third-generation EGFR TKI. It compared ivonescimab plus platinum-containing chemotherapy with placebo plus chemotherapy.
Key Findings:
HARMONi met its dual primary progression-free survival endpoints.
Overall survival showed a favorable trend but did not reach statistical significance.
The FDA said the progression-free survival benefit alone did not support a favorable benefit-risk profile or establish substantial evidence of effectiveness.
Interpretation:
Summit Therapeutics said ivonescimab remains investigational and is not approved in the United States; it has marketing authorization in China.
Limitations:
The context does not provide trial participant numbers, effect estimates, or detailed safety results.
Conclusion:
Summit said development continues in other settings, including first-line NSCLC and colorectal cancer.